E
Evan Y. Yu
Researcher at University of Washington
Publications - 330
Citations - 19023
Evan Y. Yu is an academic researcher from University of Washington. The author has contributed to research in topics: Prostate cancer & Medicine. The author has an hindex of 44, co-authored 264 publications receiving 14899 citations. Previous affiliations of Evan Y. Yu include Seattle Cancer Care Alliance & Harvard University.
Papers
More filters
Journal ArticleDOI
Integrative clinical genomics of advanced prostate cancer
Dan R. Robinson,Eliezer M. Van Allen,Eliezer M. Van Allen,Yi-Mi Wu,Nikolaus Schultz,Robert J. Lonigro,Juan Miguel Mosquera,Bruce Montgomery,Mary-Ellen Taplin,Colin C. Pritchard,Gerhardt Attard,Gerhardt Attard,Himisha Beltran,Wassim Abida,Robert K. Bradley,Jake Vinson,Xuhong Cao,Pankaj Vats,Lakshmi P. Kunju,Maha Hussain,Felix Y. Feng,Scott A. Tomlins,Kathleen A. Cooney,David Smith,Christine Brennan,Javed Siddiqui,Rohit Mehra,Yu Chen,Yu Chen,Dana E. Rathkopf,Dana E. Rathkopf,Michael J. Morris,Michael J. Morris,Stephen B. Solomon,Jeremy C. Durack,Victor E. Reuter,Anuradha Gopalan,Jianjiong Gao,Massimo Loda,Rosina T. Lis,Michaela Bowden,Michaela Bowden,Stephen P. Balk,Glenn C. Gaviola,Carrie Sougnez,Manaswi Gupta,Evan Y. Yu,Elahe A. Mostaghel,Heather H. Cheng,Hyojeong Mulcahy,Lawrence D. True,Stephen R. Plymate,Heidi Dvinge,Roberta Ferraldeschi,Roberta Ferraldeschi,Penny Flohr,Penny Flohr,Susana Miranda,Susana Miranda,Zafeiris Zafeiriou,Zafeiris Zafeiriou,Nina Tunariu,Nina Tunariu,Joaquin Mateo,Joaquin Mateo,Raquel Perez-Lopez,Raquel Perez-Lopez,Francesca Demichelis,Francesca Demichelis,Brian D. Robinson,Marc H. Schiffman,David M. Nanus,Scott T. Tagawa,Alexandros Sigaras,Kenneth Eng,Olivier Elemento,Andrea Sboner,Elisabeth I. Heath,Howard I. Scher,Howard I. Scher,Kenneth J. Pienta,Philip W. Kantoff,Johann S. de Bono,Johann S. de Bono,Mark A. Rubin,Peter S. Nelson,Levi A. Garraway,Levi A. Garraway,Charles L. Sawyers,Arul M. Chinnaiyan +89 more
TL;DR: This cohort study provides clinically actionable information that could impact treatment decisions for affected individuals and identified new genomic alterations in PIK3CA/B, R-spondin, BRAF/RAF1, APC, β-catenin, and ZBTB16/PLZF.
Journal ArticleDOI
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Charles J. Ryan,Matthew R. Smith,Johann S. de Bono,Arturo Molina,Christopher J. Logothetis,Paul de Souza,Karim Fizazi,Paul N. Mainwaring,Josep M. Piulats,Siobhan Ng,Joan Carles,Peter F.A. Mulders,Ethan Basch,Eric J. Small,Fred Saad,D. Schrijvers,Hendrik Van Poppel,Som D. Mukherjee,Henrik Suttmann,Winald R. Gerritsen,Thomas W. Flaig,Daniel J. George,Evan Y. Yu,Eleni Efstathiou,Allan J. Pantuck,Eric Winquist,Celestia S. Higano,Mary-Ellen Taplin,Youn C. Park,Thian Kheoh,Thomas W. Griffin,Howard I. Scher,Dana E. Rathkopf +32 more
TL;DR: Abiraterone improved radiographic progression-free survival, showed a trend toward improved overall survival, and significantly delayed clinical decline and initiation of chemotherapy in patients with metastatic castration-resistant prostate cancer.
Journal ArticleDOI
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.
Arjun Vasant Balar,Matthew D. Galsky,Jonathan E. Rosenberg,Thomas Powles,Daniel P. Petrylak,Joaquim Bellmunt,Yohann Loriot,Andrea Necchi,Jean H. Hoffman-Censits,Jose Luis Perez-Gracia,Nancy A. Dawson,Michiel S. van der Heijden,Robert Dreicer,Sandy Srinivas,Margitta Retz,Richard W. Joseph,Alexandra Drakaki,Ulka N. Vaishampayan,Srikala S. Sridhar,David I. Quinn,Ignacio Duran,David R. Shaffer,Bernhard J. Eigl,Petros Grivas,Evan Y. Yu,S. Li,Edward E. Kadel,Zachary Boyd,Richard Bourgon,Priti S. Hegde,Sanjeev Mariathasan,Ann Christine Thastrom,Oyewale O. Abidoye,Gregg Fine,Dean F. Bajorin +34 more
TL;DR: Atezolizumab showed encouraging durable response rates, survival, and tolerability, supporting its therapeutic use in untreated metastatic urothelial cancer.
Journal ArticleDOI
Lentivirus-delivered stable gene silencing by RNAi in primary cells.
Sheila A. Stewart,Derek M. Dykxhoorn,Deborah Palliser,Hana Mizuno,Evan Y. Yu,Dong Sung An,David M. Sabatini,Irvin S. Y. Chen,William C. Hahn,Phillip A. Sharp,Robert A. Weinberg,Carl D. Novina +11 more
TL;DR: It is demonstrated that both Moloney leukemia virus and lentivirus vector-mediated expression of RNAi can achieve effective, stable gene silencing in diverse biological systems and will assist in elucidating gene functions in numerous cell types including primary cells.
Journal ArticleDOI
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.
Howard I. Scher,Tomasz M. Beer,Celestia S. Higano,Aseem Anand,Mary-Ellen Taplin,Eleni Efstathiou,Dana E. Rathkopf,Julia Shelkey,Evan Y. Yu,Joshi J. Alumkal,David T. Hung,Mohammad Hirmand,Lynn Seely,Michael J. Morris,Daniel C. Danila,John L. Humm,Steve Larson,Martin Fleisher,Charles L. Sawyers,Charles L. Sawyers +19 more
TL;DR: The results of this phase 1-2 trial validate in man preclinical studies implicating sustained androgen-receptor signalling as a driver in this disease.